Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Zevalin effective and safe in refractory, heavily pretreated NHL patients

Oct. 30, 2000

Boehringer Ingelheim presents new series of inhibitors of signal transduction

Oct. 30, 2000

Patient enrollment begins in phase I trial of Cotara for colorectal cancer

Oct. 30, 2000

Substituted aza-oxindoles which inhibit protein tyrosine or serine/threonine kinases

Oct. 30, 2000

Antisoma licenses thioplatin from German cancer center

Oct. 30, 2000

Chemotherapeutic potential of competitive glyoxalase I inhibitor evaluated in tumor-bearing mice

Oct. 30, 2000

Alza's Caelyx approved in E.U. for advanced ovarian cancer

Oct. 27, 2000

MacroMed's OncoGel enters phase I

Oct. 27, 2000

Triazine derivative inhibits angiogenesis in vivo

Oct. 27, 2000

Leukemia treatment designated an orphan drug in Europe

Oct. 26, 2000

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...